Literature DB >> 26701666

Advances in and Algorithms for the Treatment of Relapsing-Remitting Multiple Sclerosis.

Jens Ingwersen1, Orhan Aktas1, Hans-Peter Hartung2.   

Abstract

Treatment options in relapsing-remitting multiple sclerosis have increased considerably in recent years; currently, a dozen different preparations of disease-modifying therapies are available and some more are expected to be marketed soon. For the treating neurologist this broad therapeutic repertoire not only greatly improves individualized management of the disease, but also makes choices more complex and difficult. A number of factors must be considered, including disease activity and severity, safety profile, and patient preference. We here discuss the currently existing options and suggest treatment algorithms for managing relapsing-remitting multiple sclerosis.

Entities:  

Keywords:  Disease-modifying therapy; Relapsing-remitting multiple sclerosis; Treatment algorithm; Treatment decisions

Mesh:

Substances:

Year:  2016        PMID: 26701666      PMCID: PMC4720679          DOI: 10.1007/s13311-015-0412-4

Source DB:  PubMed          Journal:  Neurotherapeutics        ISSN: 1878-7479            Impact factor:   7.620


  99 in total

1.  Disease activity free status: a new end point for a new era in multiple sclerosis clinical research?

Authors:  Carolyn J Bevan; Bruce A C Cree
Journal:  JAMA Neurol       Date:  2014-03       Impact factor: 18.302

Review 2.  Aggressive multiple sclerosis: proposed definition and treatment algorithm.

Authors:  Carolina A Rush; Heather J MacLean; Mark S Freedman
Journal:  Nat Rev Neurol       Date:  2015-06-02       Impact factor: 42.937

3.  PML in a patient treated with fumaric acid.

Authors:  Ummehan Ermis; Joachim Weis; Jörg B Schulz
Journal:  N Engl J Med       Date:  2013-04-25       Impact factor: 91.245

4.  Scoring treatment response in patients with relapsing multiple sclerosis.

Authors:  M P Sormani; J Rio; M Tintorè; A Signori; D Li; P Cornelisse; B Stubinski; M l Stromillo; X Montalban; N De Stefano
Journal:  Mult Scler       Date:  2012-09-25       Impact factor: 6.312

5.  Neurobiological effects of sphingosine 1-phosphate receptor modulation in the cuprizone model.

Authors:  Hye Jung Kim; Veronique E Miron; Danuta Dukala; Richard L Proia; Samuel K Ludwin; Maria Traka; Jack P Antel; Betty Soliven
Journal:  FASEB J       Date:  2011-01-19       Impact factor: 5.191

6.  Fingolimod versus interferon beta/glatiramer acetate after natalizumab suspension in multiple sclerosis.

Authors:  Pietro Iaffaldano; Giuseppe Lucisano; Carlo Pozzilli; Vincenzo Brescia Morra; Angelo Ghezzi; Enrico Millefiorini; Francesco Patti; Alessandra Lugaresi; Giovanni Bosco Zimatore; Maria Giovanna Marrosu; Maria Pia Amato; Antonio Bertolotto; Roberto Bergamaschi; Franco Granella; Gabriella Coniglio; Gioacchino Tedeschi; Patrizia Sola; Giacomo Lus; Maria Teresa Ferrò; Gerardo Iuliano; Francesco Corea; Alessandra Protti; Paola Cavalla; Angelica Guareschi; Mariaemma Rodegher; Damiano Paolicelli; Carla Tortorella; Vito Lepore; Luca Prosperini; Francesco Saccà; Damiano Baroncini; Giancarlo Comi; Maria Trojano
Journal:  Brain       Date:  2015-09-11       Impact factor: 13.501

7.  Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) study.

Authors:  Eva Havrdova; Steven Galetta; Michael Hutchinson; Dusan Stefoski; David Bates; Chris H Polman; Paul W O'Connor; Gavin Giovannoni; J Theodore Phillips; Fred D Lublin; Amy Pace; Richard Kim; Robert Hyde
Journal:  Lancet Neurol       Date:  2009-02-07       Impact factor: 44.182

8.  Lipoatrophy in patients with multiple sclerosis on glatiramer acetate.

Authors:  Catherine M Edgar; Donald G Brunet; Paul Fenton; E Vee McBride; Peter Green
Journal:  Can J Neurol Sci       Date:  2004-02       Impact factor: 2.104

Review 9.  Alemtuzumab for the treatment of multiple sclerosis.

Authors:  Mark D Willis; Neil P Robertson
Journal:  Ther Clin Risk Manag       Date:  2015-03-31       Impact factor: 2.423

Review 10.  Stratification and monitoring of natalizumab-associated progressive multifocal leukoencephalopathy risk: recommendations from an expert group.

Authors:  C McGuigan; M Craner; J Guadagno; R Kapoor; G Mazibrada; P Molyneux; R Nicholas; J Palace; O R Pearson; D Rog; C A Young
Journal:  J Neurol Neurosurg Psychiatry       Date:  2015-10-22       Impact factor: 10.154

View more
  17 in total

1.  Neuro-Immunotherapies: A 30-year Retrospective of an Overwhelming Success and a Brighter Future.

Authors:  Marinos C Dalakas
Journal:  Neurotherapeutics       Date:  2016-01       Impact factor: 7.620

Review 2.  Treatment-Related Progressive Multifocal Leukoencephalopathy in Multiple Sclerosis: A Comprehensive Review of Current Evidence and Future Needs.

Authors:  Emanuele D'Amico; Aurora Zanghì; Carmela Leone; Hayrettin Tumani; Francesco Patti
Journal:  Drug Saf       Date:  2016-12       Impact factor: 5.606

3.  Lateral and escalation therapy in relapsing-remitting multiple sclerosis: a comparative study.

Authors:  Emanuele D'Amico; Carmela Leone; Aurora Zanghì; Salvatore Lo Fermo; Francesco Patti
Journal:  J Neurol       Date:  2016-06-17       Impact factor: 4.849

4.  Regulatory B Cells Normalize CNS Myeloid Cell Content in a Mouse Model of Multiple Sclerosis and Promote Oligodendrogenesis and Remyelination.

Authors:  Andrea Pennati; Emily A Nylen; Ian D Duncan; Jacques Galipeau
Journal:  J Neurosci       Date:  2020-05-19       Impact factor: 6.167

5.  Innovative Medical Technology and the Treatment Decision-Making Process in Multiple Sclerosis: A Focus Group Study to Examine Patient Perspectives.

Authors:  L A Visser; M De Mul; W K Redekop
Journal:  Patient Prefer Adherence       Date:  2021-05-07       Impact factor: 2.711

Review 6.  Role of Monoclonal Antibody "Alemtuzumab" in the Treatment of Multiple Sclerosis.

Authors:  Sadia Nosher; Sehrish Fuad; Nupur Mishra; Zaid A Alrashid; Bindu Rathod; Devyani Mohan; Deepak M Basavanagowda; Arveen Kaur; Stacey E Heindl
Journal:  Cureus       Date:  2021-02-09

Review 7.  Daclizumab: A Review in Relapsing Multiple Sclerosis.

Authors:  Matt Shirley
Journal:  Drugs       Date:  2017-03       Impact factor: 11.431

Review 8.  Benefit-Risk of Therapies for Relapsing-Remitting Multiple Sclerosis: Testing the Number Needed to Treat to Benefit (NNTB), Number Needed to Treat to Harm (NNTH) and the Likelihood to be Helped or Harmed (LHH): A Systematic Review and Meta-Analysis.

Authors:  Diogo Mendes; Carlos Alves; Francisco Batel-Marques
Journal:  CNS Drugs       Date:  2016-10       Impact factor: 6.497

Review 9.  The sequence of disease-modifying therapies in relapsing multiple sclerosis: safety and immunologic considerations.

Authors:  Gabriel Pardo; David E Jones
Journal:  J Neurol       Date:  2017-09-06       Impact factor: 4.849

10.  Redox Events As Modulators of Pathology and Therapy of Neuroinflammatory Diseases.

Authors:  Klaudia Lepka; Carsten Berndt; Hans-Peter Hartung; Orhan Aktas
Journal:  Front Cell Dev Biol       Date:  2016-06-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.